SCHEMBL5149134

SCHEMBL5149134

Cc1ccc(C(=O)N[C@@H](CO)Cc2c[nH]c3ccccc23)cc1-c1ccc(CO)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERAP2 Q6P179 1/20 0.48
TACR1 P25103 5/20 0.47
HDAC3 O15379 5/20 0.47
HDAC1 Q13547 5/20 0.47
HDAC2 Q92769 5/20 0.47
HDAC4 P56524 4/20 0.47
HDAC7 Q8WUI4 4/20 0.47
HDAC10 Q969S8 4/20 0.47
HDAC11 Q96DB2 4/20 0.47
HDAC8 Q9BY41 4/20 0.47
HDAC6 Q9UBN7 4/20 0.47
HDAC9 Q9UKV0 4/20 0.47
HDAC5 Q9UQL6 4/20 0.47
HPGDS O60760 1/20 0.47
CDK4 P11802 1/20 0.46
CCND1 P24385 1/20 0.46
ITGB2 P05107 2/20 0.45
ICAM1 P05362 2/20 0.45
ITGAL P20701 2/20 0.45
LNPEP Q9UIQ6 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5151625 0.93 ERAP2 (0.48) ERAP2TACR1HDAC3HDAC1HDAC2
SCHEMBL5151626 0.88 KMT2A (0.56) ERAP2HDAC3HDAC1HDAC2HDAC4
SCHEMBL5154756 0.87 ITGB2 (0.47) ERAP2TACR1HDAC3HDAC1HDAC2
SCHEMBL4601988 0.87 CDK4 (0.57) ERAP2TACR1HDAC3HDAC1HDAC2
SCHEMBL5149264 0.86 ERAP2 (0.47) ERAP2TACR1HDAC3HDAC1HDAC2
SCHEMBL5154591 0.86 MEN1 (0.49) ERAP2TACR1HDAC3HDAC1HDAC2
SCHEMBL5152074 0.85 MEN1 (0.49) HDAC3HDAC1HDAC2HDAC4HDAC7
SCHEMBL4601042 0.84 CDK4 (0.53) HDAC3HDAC1HDAC2HDAC4HDAC7
SCHEMBL13912823 0.82 TACR1 (0.52) ERAP2TACR1HDAC3HDAC1HDAC2
SCHEMBL13902827 0.82 TACR1 (0.55) ERAP2TACR1HDAC3HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070060573-A1 Acyltryptophanols BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-03-15 US claimed
US-20070060573-A1 Acyltryptophanols BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-03-15 US disclosed
US-20070060573-A1 Acyltryptophanols BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-03-15 US disclosed
US-20070060573-A1 Acyltryptophanols BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070060573-A1 Acyltryptophanols FSHR, NPY1R, NPY2R ERAP2 1644/4885TACR1 87/4885HDAC3 736/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.